Clinical trial · Observational
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
Unmasking Polycythemia Vera in Long-Standing Essential Thrombocythemia: A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
NCT07203768CI-TRIAL-00117431ET2PVrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
International multicenter retrospective observational study consisting of two parts: a nested case-control study (part A) and a comparative retrospective cohort study (part B).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycythemia Vera | Polycythemia Vera | ONTOLOGY_EXACT | 0.98 |
| Thrombocythemia | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- ET to PV patients
- description
- Patients JAK2V617F positive and who have progressed to PV by 31/12/2020.
- label
- ET patients
- description
- Patients JAK2V617F positive who did not progress to PV after a comparable period of time. This control group will be selected using a 1:1 matched case-control design.
- label
- PV de novo patients
- description
- Patients diagnosed with de novo PV (no progression from previous ET). This control group will be recruited using a 1:1 matching procedure.
Primary outcomes (2)
- measure
- Nested case-control study
- timeFrame
- Up to the baseline
- description
- To identify proliferative risk factors for progression from ET to PV in JAK2V617F positive patients.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: \- ET patients (diagnosed according to "International consensus classification of myeloid neoplasms and acute leukemias - 2022" criteria) who are JAK2V617F positive and have progressed to PV (diagnosed according to "International consensus classification of myeloid neoplasms and acute leukemias - 2022" criteria) by 31/12/2020. The date of PV diagnosis will be defined as the index date and this group of patients will be defined as ET-to-PV cases. Exclusion Criteria: * None.
References
Publications (1)
- DERIVEDBarbui T, Thiele J, Alvarez-Larran A, Rambaldi A, Vannucchi AM, Tefferi A. From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a multicenter ELN study. Ann Hematol. 2026 Mar 4;105(4):158. doi: 10.1007/s00277-026-06898-1. PMID 41776088